 |
Description
Oncothyreon's lead compound targeting the PI-3K/AKT pathway is PX-866. This small molecule has demonstrated inhibitory activity against the α, Υ and σ forms of PI-3K. Unlike other therapies that target PI-3K, PX-866 is an irreversible PI-3K inhibitor. This irreversible binding contributes to the potent in vivo activity of PX-866 relative to other reversible PI-3K inhibitors.
Preclinical studies demonstrated that PX-866 induces prolonged inhibition of tumor PI-3K signaling following both oral and intravenous administration, and has potent in vivo anti-tumor activity in human ovarian cancer, lung cancer, and intracranial glioma tumor models. PX-866 also has been shown to enhance the activity of cytotoxic agents and other targeted therapies, including gefitinib and bevacizumab, in preclinical studies.
|
|
